Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Short term Debt (2021 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Short term Debt for 3 consecutive years, with $11.0 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Short term Debt fell 21.48% year-over-year to $11.0 million, compared with a TTM value of $11.0 million through Mar 2023, down 21.48%, and an annual FY2022 reading of $16.8 million, up 113.08% over the prior year.
  • Short term Debt was $11.0 million for Q1 2023 at Alaunos Therapeutics, down from $16.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $22.7 million in Q3 2022 and bottomed at $7.9 million in Q4 2021.
  • Average Short term Debt over 3 years is $14.9 million, with a median of $14.0 million recorded in 2022.
  • The sharpest move saw Short term Debt skyrocketed 113.08% in 2022, then fell 21.48% in 2023.
  • Year by year, Short term Debt stood at $7.9 million in 2021, then surged by 113.08% to $16.8 million in 2022, then plummeted by 34.46% to $11.0 million in 2023.
  • Business Quant data shows Short term Debt for TCRT at $11.0 million in Q1 2023, $16.8 million in Q4 2022, and $22.7 million in Q3 2022.